Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis

Mazzella, Giuseppe; Accogli, Esterita; Sottili, S.; Festi, Davide; Orsini, M.; Salzetta, Antonio; Novelli, Vieri; Cipolla, Antonio; Fabbri, Carlo; Pezzoli, Alessandro; Roda, Enrico

doi:10.1016/s0168-8278(96)80022-5

Cited by 281 publications

(200 citation statements)

References 39 publications

Supporting

Mentioning

192

Contrasting

Unclassified

Order By: Relevance

“…mm 3 ; 130 1 10 9 /L) identified a subgroup of patients with (Adapted and reprinted with permission. 7 ) approximately a twofold increased mortality compared with cirrhotic patients without these features. These findings showed that subtle differences in patient characteristics between studies could account for marked difference in patient genesis, such as alcohol consumption and smoking, but it was unclear whether the investigators controlled for factors outcomes.…”

mentioning

confidence: 96%

“…Further studies of effects of therapy with alpha interferon in patients with cirrhosis caused by hepatitis C has been assessed in one pro-larger numbers of responders and longer follow-up evaluation are needed to prove that HCV clearance and subsequent spective and two large retrospective studies comprising 703 patients. [5][6][7] In these studies, the major focus was on whether decrease in hepatic inflammation and necrosis are associated with a significant reduction in the incidence of HCC. interferon therapy reduced the incidence of HCC.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Therapy of hepatitis C: Patients with cirrhosis

1997

View full text Add to dashboard Cite

The management of both compensated and decompensated progressed to cirrhosis is estimated to be 20% to 30%. 1 In addition to patients who present with symptoms or signs cirrhosis caused by hepatitis C must be viewed in the context of the natural history of the disease. The prognosis of compen-of chronic hepatitis C, a proportion present initially with complications of cirrhosis such as variceal bleeding, ascites, sated cirrhosis caused by hepatitis C is relatively good. In a recent retrospective study, after 5 years of follow-up evalua-or hepatocellular carcinoma (HCC). For countries in North America and Europe with a prevalence of chronic HCV infection, 18% of patients had developed hepatic decompensation and 7% hepatocellular carcinoma. Overall 5-year survival rate tion in the general population of 0.5% to 2%, one can estimate that at least 0.1% (1,000 per million) of the population was 91%. Treatment with alpha interferon appears to decrease the incidence of hepatocellular carcinoma in patients who have cirrhosis caused by hepatitis C.Spontaneous resolution of disease and loss of viral replicaachieve a sustained remission. However, on an intention-totreat basis and after adjustment for differences in clinical tion is rare during the course of chronic hepatitis C. 2 Accordingly, patients with cirrhosis caused by HCV are likely to and serological features at entry, interferon therapy does not correlate with a reduced incidence of liver cancer or improved progress steadily, eventually developing complications of hepatic failure or HCC or require liver transplantation. Death survival. Combined analysis of multiple large studies on patients with cirrhosis caused by hepatitis C indicates that cur-from liver-related causes has been shown to account for 70% of the mortality in patients with cirrhosis caused by hepatitis rent regimens of alpha interferon (3 to 6 million units three times weekly for 6 to 12 months) result in a sustained bio-C, 3 compared with only 3% of patients overall with hepatitis C. 4 The patient with cirrhosis caused by hepatitis C constichemical response in 9% of patients. The rates of sustained virological responses are less well documented. Virological tutes an important therapeutic challenge.The management of both compensated and decompenmeasurements during therapy show that only 22% of patients become hepatitis C virus (HCV) RNA negative by 4 weeks sated cirrhosis should be viewed in the context of the natural history of the disease. Recent reports have suggested that and, thereafter, there is a high rate of breakthrough. In small studies, the combination of interferon and ribavirin leads to alpha interferon therapy may reduce the risk of HCC in patients with cirrhosis. 5 At the same time, interferon is rarely sustained biochemical and virological response rates of 21%, more than twice the rates achieved with interferon alone. The effective in inducing lasting remissions in patients with preexisting cirrhosis. Thus, the role of alpha interferon therapy prognosis of decompensated cirrhosis c...

show abstract

mentioning

confidence: 96%

mentioning

confidence: 99%

Therapy of hepatitis C: Patients with cirrhosis

1997

View full text Add to dashboard Cite

show abstract

“…Therefore, it is very important to prevent recurrence. Recent studies have shown that IFN therapy is associated with reducing the incidence of HCCin patients with chronic hepatitis C and type C cirrhosis (3,4). Wehave also reported previously the results of a case showing the effect of IFNtherapy in preventing HCCrecurrence (5).…”

Section: Discussionmentioning

confidence: 83%

Interferon Therapy for Hapatitis C Virus (HCV)-related Advanced Chronic Hepatitis after Treatment of Recurrent Hepatocellular Carcinoma: A Successful Case.

Kudo

Terao

Arita³

et al. 2002

Intern. Med.

View full text Add to dashboard Cite

A complete response was obtained by interferon (IFN) therapy for hepatitis C virus (HCV)-related advanced chronic hepatitis after curative treatment of initial and recurrent hepatocellular carcinoma (HCC). The patient is alive 73 months after diagnosis of initial HCCand is in a tumor-free state 53 months after diagnosis of the last HCC. This case suggest that it is possible to suppress recurrence and to prolong the life of patients with HCV-related advanced chronic hepatitis, if a complete response is obtained by means of IFN therapy after the curative treatment of the recurrent HCC. (Internal Medicine 41 : 202-206, 2002)

show abstract

“…[28][29][30] Currently, it is reported that IFN has highly suppressive effects not only at the early stage of hepatocarcinogenesis but also on the recurrence of HCC after curative treatment in patients with chronic viral hepatitis. [31][32][33][34] Although these suppressive effects of IFN on recurrence of HCC are still controversial, several meta-analyses have demonstrated that IFN has a significant beneficial effect after curative treatment for HCC in terms of both survival and tumor recurrence. 2,35 Such various results regarding IFN therapy suggest that IFN used postoperatively may inhibit or at least retard HCC recurrence in part if applied carefully under highly selected conditions, like MTA1-positive HCC, and is not for all patients.…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1‐positive hepatocellular carcinoma

Lee

Chung

Kim

et al. 2013

Cancer

View full text Add to dashboard Cite

BACKGROUND: Metastatic tumor antigen 1 (MTA1) overexpression is closely associated with postoperative recurrence of hepatocellular carcinoma (HCC). It has been suggested that pegylated interferon (Peg-IFN) can prevent the occurrence of HCC in patients who have chronic viral hepatitis. In this study, the authors examined whether postoperative adjuvant Peg-IFN therapy can reduce the recurrence of MTA1-positive HCC after curative surgical resection. METHODS: In this case-control study, 93 patients with MTA1-positive HCC who underwent curative surgical resection were prospectively enrolled. The median patient age was 53 years (range, 27-78); there were 65 men and 28 women; the etiology was hepatitis B virus (HBV) in 77 patients, hepatitis C virus (HCV) in 6 patients, and non-HBV/non-HCV in 10 patients; 31 patients received Peg-IFN (Peg-INTRON V R ) subcutaneously at a dose of 50 lg per week for 12 months (the Peg-IFN group); and the remaining 62 patients were followed only and did not receive any adjuvant therapies (control group). Patients were followed every 1 to 3 months for a median of 24 months. RESULTS: HCC recurred postoperatively in 26 of 93 patients (28%), and 9 patients (10%) died during follow-up. The overall cumulative recurrence rates were significantly lower in the Peg-IFN group than in the control group (7% and 14% vs 24% and 34% at 1 year and 2 years, respectively; P <.05). In addition, the 1-year and 2-year cumulative survival rates were higher in the Peg-IFN group compared with the control group (100% vs 93% and 100% vs 87%, respectively; P <.05). In multivariate analysis, the receipt of adjuvant Peg-IFN therapy, in addition to having a lower Cancer of the Liver Italian Program score and being a woman, was an independent, favorable factor for a lower risk of postoperative recurrence. INTRODUCTIONHepatocellular carcinoma (HCC) is characterized by its high prevalence and aggressiveness, which accounts for a major cause of death in the Far East and in sub-Saharan Africa. 1,2 Clinically, only less than 10% to 20% of patients with HCC have previously been considered candidates for surgical resection. 3-5 Furthermore, frequent marginal or remote recurrence of HCC in the remnant liver is another insurmountable problem in light of long-term prognosis. 6,7 According to previous studies, postoperative recurrence rates after surgical resection reached approximately 50% to 80%, whereas our recent studies reported relatively lower recurrence rates. [8][9][10][11][12] Metastatic tumor antigen 1 (MTA1) plays an important role in the tumorigenesis and metastasis of various human malignancies, such as liver, breast, prostate, lung, colorectal, and gastric cancers. 13,14 Our recent study demonstrated that MTA1 overexpression is associated with frequent postoperative recurrence as well as microvascular invasion compared with negative MTA1 status and, consequently, can be used a valuable predictor of worse postoperative outcomes for patients who have HCC with respect to recurrence and survival. 15 Such findings are i...

show abstract

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis

Cited by 281 publications

References 39 publications

Therapy of hepatitis C: Patients with cirrhosis

Therapy of hepatitis C: Patients with cirrhosis

Interferon Therapy for Hapatitis C Virus (HCV)-related Advanced Chronic Hepatitis after Treatment of Recurrent Hepatocellular Carcinoma: A Successful Case.

Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1‐positive hepatocellular carcinoma

Contact Info

Product

Resources

About